title: Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
abstract: Cells expressing oncogenic c-Myc are sensitized to TNF superfamily proteins. c-Myc also is an important factor in determining whether a cell is sensitive to TRAIL-induced apoptosis, and it is well established that the mitochondrial pathway is essential for apoptosis induced by c-Myc. We investigated whether c-Myc action on the mitochondria is required for TRAIL sensitivity and found that Myc sensitized cells with defective intrinsic signaling to TRAIL. TRAIL induced expression of antiapoptotic Mcl-1 and cIAP2 through activation of NF-kappaB. Both Myc and the multikinase inhibitor sorafenib block NF-kappaB. Combining sorafenib with TRAIL in vivo showed dramatic efficacy in TRAIL-resistant tumor xenografts. We propose the combination of TRAIL with sorafenib holds promise for further development.
authors.affiliation: Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
authors.forename: M Stacey
authors.initials: MS
authors.lastname: Ricci
authors.forename: Seok-Hyun
authors.initials: SH
authors.lastname: Kim
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Ogi
authors.forename: John P
authors.initials: JP
authors.lastname: Plastaras
authors.forename: Jianhua
authors.initials: J
authors.lastname: Ling
authors.forename: Wenge
authors.initials: W
authors.lastname: Wang
authors.forename: Zhaoyu
authors.initials: Z
authors.lastname: Jin
authors.forename: Yingqiu Y
authors.initials: YY
authors.lastname: Liu
authors.forename: David T
authors.initials: DT
authors.lastname: Dicker
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Chiao
authors.forename: Keith T
authors.initials: KT
authors.lastname: Flaherty
authors.forename: Charles D
authors.initials: CD
authors.lastname: Smith
authors.forename: Wafik S
authors.initials: WS
authors.lastname: El-Deiry
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D001557:Benzenesulfonates / Q000494:pharmacology*; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008819:Mice, Nude; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009363:Neoplasm Proteins / Q000235:genetics / Q000502:physiology*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000502:physiology*; D016271:Proto-Oncogene Proteins c-myc / Q000502:physiology*; D011725:Pyridines / Q000494:pharmacology*; D000077157:Sorafenib; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000502:physiology*; D014158:Transcription, Genetic / Q000502:physiology; D044767:Ubiquitin-Protein Ligases
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D051034:Inhibitor of Apoptosis Proteins; C579094:Mcl1 protein, mouse; D064549:Myeloid Cell Leukemia Sequence 1 Protein; D009363:Neoplasm Proteins; D010671:Phenylurea Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D016271:Proto-Oncogene Proteins c-myc; D011725:Pyridines; D053221:TNF-Related Apoptosis-Inducing Ligand; C505653:TNFSF10 protein, human; D009536:Niacinamide; D000077157:Sorafenib; C494832:BIRC3 protein, human; D000075747:Baculoviral IAP Repeat-Containing 3 Protein; D044767:Ubiquitin-Protein Ligases